Telomerase as an emerging target to fight cancer--opportunities and challenges for nanomedicine.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractTelomerase as an enzyme is responsible for the renewal of the chromosomal ends, the so-called telomeres. By preventing them from shortening with each cell cycle, telomerase is able to inhibit cellular senescence and apoptosis. Telomerase activity, which is detectable in the majority of cancer cells, allows them to maintain their proliferative capacity. The thus obtained immortality of those cells again is a key to their malignancy. Based on these discoveries, it is obvious that telomerase inhibitors would represent an innovative approach to fight cancer, and a variety of such candidate molecules are currently in the pipeline. Telomerase inhibitors largely fall in two classes of compounds: small synthetic molecules and nucleotide-based biologicals. For several candidates, some proof of concept studies have been demonstrated, either on cell cultures or in animal models. But the same studies also revealed that inefficient delivery is largely limiting the translational step into the clinic. The most appealing feature of telomerase inhibitors, which distinguishes them from conventional anticancer drugs, is probably seen in their intrinsic non-toxicity to normal cells. Nevertheless, efficient delivery to the target cells, i.e. to the tumor, is still required. Here, some well-known biopharmaceutical problems such as insufficient solubility, permeability or even metabolic stability are frequently encountered. To address these challenges, there is a clear need for adequate delivery technologies, for example by using nanomedicines, that would allow to overcome their biopharmaceutical shortcomings and to warrant a sufficient bioavailability at the target side. This review first briefly explains the concept of telomerase and telomerase inhibition in cancer therapy. It secondly aims to provide an overview of the different currently known telomerase inhibitors. Finally, the biopharmaceutical limitations of these molecules are discussed as well as the possibilities to overcome those limits by novel drug carrier systems and formulation approaches.
CitationTelomerase as an emerging target to fight cancer--opportunities and challenges for nanomedicine. 2010, 146 (2):228-40 J Control Release
AffiliationDepartment of Biopharmaceutics and Pharmaceutical Technology, Saarland University, Saarbrücken, Germany.
The following license files are associated with this item:
- Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease.
- Authors: Tárkányi I, Aradi J
- Issue date: 2008 Jan
- Telomere biology of pediatric cancer.
- Authors: Tabori U, Dome JS
- Issue date: 2007 Apr-May
- Telomerase as a diagnostic and therapeutic target for cancer.
- Authors: Doyle LA, Highsmith WE
- Issue date: 2002 Apr
- Telomeres and telomerase as targets for cancer therapy.
- Authors: Zimmermann S, Martens UM
- Issue date: 2007 Apr
- Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
- Authors: Kelland LR
- Issue date: 2005 May